The estimated Net Worth of Matthew Norkunas is at least $493 Tausend dollars as of 15 July 2024. Dr Norkunas owns over 3,347 units of Generation Bio Co stock worth over $135,364 and over the last 4 years he sold GBIO stock worth over $0. In addition, he makes $357,646 as Chief Financial Officer at Generation Bio Co.
Dr has made over 9 trades of the Generation Bio Co stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 3,347 units of GBIO stock worth $8,167 on 15 July 2024.
The largest trade he's ever made was exercising 15,805 units of Generation Bio Co stock on 15 January 2024 worth over $38,564. On average, Dr trades about 5,306 units every 49 days since 2020. As of 15 July 2024 he still owns at least 55,477 units of Generation Bio Co stock.
You can see the complete history of Dr Norkunas stock trades at the bottom of the page.
Dr. Matthew Norkunas M.B.A., M.D. is the Chief Financial Officer at Generation Bio Co.
As the Chief Financial Officer of Generation Bio Co, the total compensation of Dr D at Generation Bio Co is $357,646. There are 2 executives at Generation Bio Co getting paid more, with Dr. Cameron Geoffrey McDonough having the highest compensation of $856,885.
Dr D is 43, he's been the Chief Financial Officer of Generation Bio Co since . There are 5 older and no younger executives at Generation Bio Co. The oldest executive at Generation Bio Co. is Dr. Robert Kotin Ph.D., 65, who is the Co-Founder & Advisor.
Matthew's mailing address filed with the SEC is C/O GENERATION BIO CO., 301 BINNEY ST, , CAMBRIDGE, MA, 02142.
Over the last 4 years, insiders at Generation Bio Co have traded over $37,722,950 worth of Generation Bio Co stock and bought 4,282,125 units worth $70,408,633 . The most active insiders traders include Jason P Rhodes, Biomedical Innovation Maste... und Public Equities, L.P.Minne .... On average, Generation Bio Co executives and independent directors trade stock every 11 days with the average trade being worth of $116,471. The most recent stock trade was executed by Yalonda Howze on 15 July 2024, trading 3,347 units of GBIO stock currently worth $8,167.
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Generation Bio Co executives and other stock owners filed with the SEC include: